Neuberger Berman Group LLC Sells 18,662 Shares of Sanofi SA (SNY)

Neuberger Berman Group LLC cut its position in shares of Sanofi SA (NYSE:SNY) by 28.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,721 shares of the company’s stock after selling 18,662 shares during the quarter. Neuberger Berman Group LLC’s holdings in Sanofi were worth $2,132,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Girard Partners LTD. acquired a new stake in Sanofi during the third quarter valued at approximately $154,000. Stratos Wealth Partners LTD. acquired a new stake in Sanofi during the third quarter valued at approximately $174,000. Quantum Capital Management acquired a new stake in Sanofi during the third quarter valued at approximately $202,000. Holderness Investments Co. acquired a new stake in Sanofi during the third quarter valued at approximately $204,000. Finally, New England Research & Management Inc. acquired a new stake in Sanofi during the third quarter valued at approximately $205,000. 7.04% of the stock is currently owned by institutional investors and hedge funds.

NYSE:SNY opened at $42.77 on Wednesday. Sanofi SA has a 1 year low of $37.43 and a 1 year high of $45.86. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. The company has a market capitalization of $108.88 billion, a PE ratio of 13.66, a PEG ratio of 2.41 and a beta of 0.67.

Sanofi (NYSE:SNY) last posted its earnings results on Wednesday, October 31st. The company reported $1.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.09. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The company had revenue of $9.39 billion during the quarter, compared to analysts’ expectations of $9.10 billion. During the same quarter in the previous year, the company posted $1.71 earnings per share. Sanofi’s quarterly revenue was up 1.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Sanofi SA will post 3.1 EPS for the current year.

A number of equities research analysts have weighed in on SNY shares. Jefferies Financial Group raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, December 11th. Zacks Investment Research raised Sanofi from a “sell” rating to a “hold” rating in a report on Tuesday, September 11th. Argus lifted their target price on shares of Sanofi from $48.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, November 8th. Barclays upgraded shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Thursday, November 1st. Finally, Morgan Stanley initiated coverage on shares of Sanofi in a research note on Friday, December 14th. They issued an “equal weight” rating for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company. Sanofi presently has a consensus rating of “Hold” and an average target price of $50.00.

WARNING: “Neuberger Berman Group LLC Sells 18,662 Shares of Sanofi SA (SNY)” was first published by Stock Observer and is the property of of Stock Observer. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.thestockobserver.com/2019/01/09/neuberger-berman-group-llc-sells-18662-shares-of-sanofi-sa-sny.html.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Recommended Story: Coverage Ratio

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply